Sign In

Felipe de Sousa e Melo

Director | Large Molecule Modalities | Induced Proximity Platform

Felipe de Sousa e Melo is a senior scientist and researcher currently working as the Director of the Induced Proximity Platform at Amgen.12 He is based in San Mateo, California, United States.12

Professional Background

Education and Early Career: Felipe holds a PhD in Oncology and Cancer Biology from the University of Amsterdam, which he completed between 2008 and 2013.12 Prior to his doctoral studies, he obtained a Master's degree in Cancer and Immunology (2006-2008) and a Bachelor of Science in Biochemistry and Molecular Biology (2002-2005).2

Career Progression: Felipe's career has been marked by steady advancement in the field of cancer research:

  • He started as a PhD student at the Academic Medical Center in Amsterdam (2008-2012).1
  • Following his PhD, he worked as a Postdoctoral Researcher at the same institution (2012-2013).1
  • He then moved to Genentech, where he served as a Postdoctoral Fellow (2014-2017) and later as a Senior Scientist (2018-present).1
  • Currently, he holds the position of Director - Induced Proximity Platform at Amgen.23

Research Focus and Expertise

Felipe leads a multidisciplinary research group focused on developing novel approaches in cancer research.1 His areas of expertise include:

  • Cancer Biology
  • Cancer Therapy
  • Cancer Diagnostics
  • Cancer Animal Models
  • Data Mining
  • Oncology4

His work has involved leveraging genome engineering technology and tumor modeling to investigate the role of cancer stem cells in tumor growth and metastasis.1

Achievements and Recognition

Throughout his career, Felipe has received several awards for his research contributions:

  • STAT Wunderkind 20191
  • Multiple AMC Publication Awards (2011, 2012, 2013)1
  • PhD Thesis Award from the Academic Medical Center Amsterdam (2013)1

Felipe de Sousa e Melo's career trajectory demonstrates his significant contributions to cancer research and his leadership in developing innovative approaches to understanding and treating cancer.

Highlights

Sep 10 · biorxiv.org
LYMTACs: Chimeric Small Molecules Repurpose Lysosomal ...

Related Questions

What is the Induced Proximity Platform at Amgen?
What are some notable achievements of Felipe de Sousa e Melo in cancer research?
How did Felipe de Sousa e Melo's work at Genentech influence his role at Amgen?
What are the main goals of the multidisciplinary research group led by Felipe de Sousa e Melo?
What awards has Felipe de Sousa e Melo received for his contributions in oncology?
Felipe de Sousa e Melo
Felipe de Sousa e Melo, photo 1
Felipe de Sousa e Melo, photo 2
Add to my network

Location

San Mateo, California, United States